HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $2.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Unicycive Therapeutics, maintaining a price target of $2.5.
September 03, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Unicycive Therapeutics, maintaining a price target of $2.5.
The reiteration of a Buy rating and maintenance of a $2.5 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Unicycive Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100